Adjusted EPS beat, revenue edged past estimates, guidance held steady

The quarter cleared the main market hurdle. Published estimates were roughly $0.84–$0.85 for adjusted EPS and $582 million–$583 million of revenue; Enovis delivered $0.90 and $582.8 million, making this a modest earnings beat with revenue essentially in line to slightly ahead.

The quality of the beat was better than the headline growth rate. Revenue rose only 3.2% reported, but organic growth was 4.8%, while adjusted EBITDA increased 14.4% and margin expanded 170 basis points to 17.9% (Financial Highlights; Adjusted EBITDA reconciliation). Gross margin also improved to 61.6% from 59.3% (Income Statement). That points to real operating leverage rather than a revenue-only result.

Reconstructive is carrying the portfolio while Prevention & Recovery remains uneven. Reconstructive revenue grew 7.5% reported and 6.3% organically, but Prevention & Recovery fell 0.8% reported and grew only 3.5% organically (Segment results). The reported P&R decline was partly caused by divestitures, yet the segment still trails the stronger momentum in Reconstructive; U.S. Other P&R revenue fell 15.8% reported despite positive organic growth.

The outlook is unchanged, not upgraded. Management reaffirmed 2026 revenue of $2.31–$2.37 billion, organic growth of 4%–6%, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free-cash-flow conversion of at least 25% (2026 guidance). That removes downside risk after the quarter, but it does not reset expectations higher. The balance sheet is still a watchpoint: cash fell to $12.6 million from $36.4 million at year-end while total debt remained about $1.28 billion (Balance Sheet; Cash Flow statement). Net read: a small operational beat with improving margins, offset by mixed segment momentum and no increase to the full-year bar.